Medical News Today: Leukemia: Do genes influence how people respond to therapy?
Some people with acute myeloid leukemia are more responsive to chemotherapy than others. Why is this, and how can this knowledge lead to better treatments? (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 13, 2018 Category: Consumer Health News Tags: Leukemia Source Type: news

UCLA Health joins nationwide clinical trial for acute myeloid leukemia
UCLA Health has joined an important national clinical trial that uses genetic testing to match people who have acute myeloid leukemia, or AML, with new therapies. UCLA ’s hospital system is the first in California to offer people the opportunity to participate.The Beat AML Master Trial will evaluate a precision-based medicine approach to treating the disease; it will allow people with the disease to have immediate access to new treatments that are currently in development without having to try more traditional approaches first. The approach could streamline a patient ’s course of treatment and, ultimately, save...
Source: UCLA Newsroom: Health Sciences - August 8, 2018 Category: Universities & Medical Training Source Type: news

Comprehensive pediatric CAR T guidelines developed by MD Anderson and PALISI
(University of Texas M. D. Anderson Cancer Center) Almost one year after the US Food and Drug Administration (FDA) approval of chimeric antigen receptor (CAR) T-cell therapy for children with acute lymphoblastic leukemia (ALL), researchers at The University of Texas MD Anderson Cancer Center and the Pediatric Acute Lung Injury and Sepsis Investigators Network (PALISI) today published treatment guidelines for managing the treatment in the online issue of Nature Reviews Clinical Oncology. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 6, 2018 Category: Cancer & Oncology Source Type: news

MD Anderson and Jazz Pharmaceuticals collaborate to evaluate treatment options for hematol
(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center and Jazz Pharmaceuticals plc today announced a five-year collaboration agreement with a goal of evaluating therapies for multiple hematologic malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 6, 2018 Category: Cancer & Oncology Source Type: news

Ivosidenib earns FDA approval against IDH1+ acute myeloid leukemia
(University of Colorado Anschutz Medical Campus) Clinical trials at CU Cancer Center and elsewhere result in FDA approval of the drug ivosidenib for the treatment of adult patients with IDH1+ AML. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - July 30, 2018 Category: Biology Source Type: news

FDA Approves Tibsovo for Acute Myeloid Leukemia
MONDAY, July 23, 2018 -- Tibsovo (ivosidenib) tablets have been approved by the U.S. Food and Drug Administration to treat relapsed or refractory acute myeloid leukemia (AML) among people with a defective IDH1 gene. Tibsovo's effectiveness was... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 23, 2018 Category: Pharmaceuticals Source Type: news

TIBSOVO (ivosidenib), an IDH1 Inhibitor Approved for Treatment of Relapsed/Refractory Acute Myeloid Leukemia with an IDH1 Mutation, Available for Order at Biologics, Inc.
CARY, N.C. (July 23, 2018) —Biologics, Inc., a McKesson Specialty Health oncology, neurology and complex care pharmacy services company, has been selected by Agios Pharmaceuticals, Inc. to be in the limited distribution network for TIBSOVO® (ivosidenib), an IDH1 inhibitor approved by the U.S. Food a... (Source: McKesson News)
Source: McKesson News - July 23, 2018 Category: Information Technology Source Type: news

Tibsovo Approved for Acute Myeloid Leukemia
Title: Tibsovo Approved for Acute Myeloid LeukemiaCategory: Health NewsCreated: 7/21/2018 12:00:00 AMLast Editorial Review: 7/23/2018 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - July 23, 2018 Category: Cancer & Oncology Source Type: news

Tibsovo Approved for Acute Myeloid Leukemia
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 20, 2018 Category: Cancer & Oncology Tags: Oncology, Pharmacy, FDA Approvals, Source Type: news

FDA Approves Tibsovo (ivosidenib) for Relapsed or Refractory Acute Myeloid Leukemia with an IDH1 Mutation
July 20, 2018 -- The U.S. Food and Drug Administration today approved Tibsovo (ivosidenib) tablets for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation. This is the first... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 20, 2018 Category: Drugs & Pharmacology Source Type: news

FDA OKs Targeted Agent Ivosidenib for Relapsed/Refractory AML FDA OKs Targeted Agent Ivosidenib for Relapsed/Refractory AML
The FDA has approved the first-in-class agent ivosidenib, which targets mutations in the IDH1 gene in acute myeloid leukemia.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 20, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Cambridge's Agios wins FDA approval for second cancer drug
The FDA approved a cancer drug from Agios Pharmaceuticals Inc. on Friday after a Phase 1 clinical study found it aided a small group of patients suffering from a rare type of leukemia. Cambridge-based Agios (Nasdaq: AGIO) is developing treatments for several types of cancer, including acute myeloid meukemia, or AML. The rare blood and bone marrow disease worsens quickly and accounts for approximately one percent of cancer patients, according to the National Cancer Institute. Las t year, Agios won… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - July 20, 2018 Category: American Health Authors: Allison DeAngelis Source Type: news

Cambridge's Agios wins FDA approval for second cancer drug
The FDA approved a cancer drug from Agios Pharmaceuticals Inc. on Friday after a Phase 1 clinical study found it aided a small group of patients suffering from a rare type of leukemia. Cambridge-based Agios (Nasdaq: AGIO) is developing treatments for several types of cancer, including acute myeloid meukemia, or AML. The rare blood and bone marrow disease worsens quickly and accounts for approximately one percent of cancer patients, according to the National Cancer Institute. Las t year, Agios won… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 20, 2018 Category: Biotechnology Authors: Allison DeAngelis Source Type: news

Tibsovo Approved for Acute Myeloid Leukemia
FRIDAY, July 20, 2018 -- Tibsovo (ivosidenib) tablets have been approved by the U.S. Food and Drug Administration to treat relapsed or refractory acute myeloid leukemia (AML) among people with a defective IDH1 gene. " The use of Tibsovo is associated... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - July 20, 2018 Category: General Medicine Source Type: news

FDA OKs Targeted Agent for Acute Myeloid Leukemia
(MedPage Today) -- Approved therapies now available for IDH1- and IDH2-mutant disease (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - July 20, 2018 Category: American Health Source Type: news

FDA approves first targeted treatment for patients with relapsed or refractory acute myeloid leukemia who have a certain genetic mutation
FDA approves new drug for the treatment of adults with acute myeloid leukemia who have a specific genetic mutation and a companion diagnostic to detect specific mutations in the IDH1 gene in patients with AML (Source: Food and Drug Administration)
Source: Food and Drug Administration - July 20, 2018 Category: American Health Source Type: news

FDA approves first targeted treatment for patients with relapsed or refractory acute myeloid leukemia who have a certain genetic mutation
The U.S. Food and Drug Administration today approved Tibsovo (ivosidenib) tablets for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation. This is the first drug in its class (IDH1 inhibitors) and is approved for use with an FDA-approved companion diagnostic used to detect specific mutations in the IDH1 gene in patients with AML. (Source: World Pharma News)
Source: World Pharma News - July 20, 2018 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Acute Kidney Injury in Patients With Cancer
Acute kidney injury (AKI) is a common complication in cancer patients and occurs in up to 30% of patients during their disease course. Multiple myeloma, leukemia/lymphoma, renal cell carcinoma, and hematopoietic stem cell transplantation are commonly associated with the development of AKI.07/19/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 19, 2018 Category: Urology & Nephrology Source Type: news

Synthetic lethality of TNK2 inhibition in PTPN11-mutant leukemia
The protein tyrosine phosphatase PTPN11 is implicated in the pathogenesis of juvenile myelomonocytic leukemia (JMML), acute myeloid leukemia (AML), and other malignancies. Activating mutations in PTPN11 increase downstream proliferative signaling and cell survival. We investigated the signaling upstream of PTPN11 in JMML and AML cells and found that PTPN11 was activated by the nonreceptor tyrosine/serine/threonine kinase TNK2 and that PTPN11-mutant JMML and AML cells were sensitive to TNK2 inhibition. In cultured human cell–based assays, PTPN11 and TNK2 interacted directly, enabling TNK2 to phosphorylate PTPN11, whic...
Source: Signal Transduction Knowledge Environment - July 17, 2018 Category: Science Authors: Jenkins, C., Luty, S. B., Maxson, J. E., Eide, C. A., Abel, M. L., Togiai, C., Nemecek, E. R., Bottomly, D., McWeeney, S. K., Wilmot, B., Loriaux, M., Chang, B. H., Tyner, J. W. Tags: STKE Research Articles Source Type: news

Researchers map 'family trees' of acute myeloid leukemia
(Comprehensive Cancer Centre Gustave Roussy) For the first time, a team of international researchers have mapped the family trees of cancer cells in acute myeloid leukemia (AML) to understand how this blood cancer responds to a new drug, enasidenib. The work also explains what happens when a patient stops responding to the treatment, providing important clues about how to combine enasidenib with other anti-cancer drugs to produce longer-lasting remissions and to prevent relapse. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 16, 2018 Category: International Medicine & Public Health Source Type: news

Girl who missed years of school fighting cancer is voted prom queen
Charlotte Jenkins, 16, from Stockport in Greater Manchester battled against a rare form of acute myeloid leukaemia to be able to sit her GCSEs and go to her end of school prom. (Source: the Mail online | Health)
Source: the Mail online | Health - July 12, 2018 Category: Consumer Health News Source Type: news

New Findings Illuminate'Black Box of Leukemia'New Findings Illuminate'Black Box of Leukemia '
Researchers have identified genetic mutations that may occur years before acute myeloid leukemia actually develops, giving new clues as to how the disease begins.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 12, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Girl, 16, who missed three years of school fighting rare cancer is voted prom queen
Charlotte Jenkins, 16, from Stockport in Greater Manchester battled against a rare form of acute myeloid leukaemia to be able to sit her GCSEs and go to her end of school prom. (Source: the Mail online | Health)
Source: the Mail online | Health - July 12, 2018 Category: Consumer Health News Source Type: news

Roche announces submission of supplemental New Drug Application for Venclexta for people with previously untreated acute myeloid leukaemia who are ineligible for intensive chemotherapy
Roche today announced submission of a supplemental New Drug Application (sNDA) to the United States (U.S.) Food and Drug Administration (FDA) for Venclexta  (venetoclax), in combination with a hypomethylating agent or in combination with low dose cytarabine (LDAC), for treatment of people with previously untreated acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. (Source: Roche Investor Update)
Source: Roche Investor Update - July 12, 2018 Category: Pharmaceuticals Source Type: news

Genetic changes in blood may predict leukemia diagnosis
Studying genetic changes in blood, researchers have found a way to identify people at high risk of developing acute myeloid leukemia years before diagnosis. (Source: Health News - UPI.com)
Source: Health News - UPI.com - July 9, 2018 Category: Consumer Health News Source Type: news

Roots of leukemia reveal possibility of predicting people at risk
(Wellcome Trust Sanger Institute) Scientists have discovered that it is possible to identify people at high risk of developing acute myeloid leukemia (AML) years before diagnosis. Wellcome Sanger Institute researchers and collaborators found that patients with AML had genetic changes in their blood years before they suddenly developed the disease. The study published in Nature shows that further research could allow earlier detection and monitoring of people at risk of AML in the future. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 9, 2018 Category: Cancer & Oncology Source Type: news

Leukemia researchers discover way to predict healthy people at risk for developing AML
(University Health Network) An international team of leukemia scientists has discovered how to predict healthy individuals at risk of developing acute myeloid leukemia (AML), an aggressive and often deadly blood cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 9, 2018 Category: Cancer & Oncology Source Type: news

FLT3 Inhibitor Quizartinib Improves Survival in AML FLT3 Inhibitor Quizartinib Improves Survival in AML
For the first time, a single agent has produced a survival benefit when compared to standard chemotherapy in a subgroup of patients with relapsed or refractory acute myeloid leukemia.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 2, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Chemotherapy May Alter Brain Activity in Survivors of Childhood ALL Chemotherapy May Alter Brain Activity in Survivors of Childhood ALL
Chemotherapy for childhood acute lymphoblastic leukemia (ALL) is associated with alterations in brain activation during attention and executive-function tasks, researchers report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 29, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

FDA Grants Priority Review for Pfizer ’s New Drug Application for Glasdegib in Patients with Previously Untreated Acute Myeloid Leukemia
June 27, 2018 - Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted the company ’s New Drug Application and granted Priority Review designation for glasdegib, an investigational oral smoothened (SMO)... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - June 27, 2018 Category: Drugs & Pharmacology Source Type: news

Amgen Receives European Commission Approval To Add Overall Survival Data To BLINCYTO ® (blinatumomab) Label
BLINCYTO is the First-and-Only Approved Bispecific CD19-Directed CD3 T Cell Engager (BiTE®) Immunotherapy THOUSAND OAKS, Calif., June 19, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has granted a full marketing authorization for BLINCYTO® (blinatumomab) based on the overall survival (OS) data from the Phase 3 TOWER study in adult patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). "BLINCYTO is the first single agent immunotherapy to demonstrate superior overall survival benefit ov...
Source: Amgen News Release - June 19, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Novel CD22 CAR-T Works After CD19 Product Failed Novel CD22 CAR-T Works After CD19 Product Failed
A novel CAR T-cell therapy directed against CD22 worked in children with acute lymphoblastic leukemia who had previously progressed after receiving CD19-directed CAR T-cell therapy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 18, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

University of Colorado Cancer Centers Study Shows that without “Yoga...
Researchers successfully target leukemia stem cells while leaving healthy blood stem cells unharmed, paving the way for "sea change" in the way we treat acute myeloid leukemia.(PRWeb June 14, 2018)Read the full story at https://www.prweb.com/releases/2018/06/prweb15553957.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - June 14, 2018 Category: Pharmaceuticals Source Type: news

Roche presents new data across a range of blood cancers at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Roche presented new data from studies in several blood cancers, including diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukaemia (CLL) and acute myeloid leukaemia (AML) at the 2018 ASCO Annual Meeting, 1-5 June, in Chicago, IL, United States. (Source: Roche Investor Update)
Source: Roche Investor Update - June 3, 2018 Category: Pharmaceuticals Source Type: news

Study of acute myeloid leukemia patients shows protein inhibitor drug safe and effective with durable remissions
(University of Texas M. D. Anderson Cancer Center) Ivosidenib, an experimental drug that inhibits a protein often mutated in several cancers has been shown to be safe, resulting in durable remissions, in a study of acute myeloid leukemia (AML) with relapsed or refractory disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 2, 2018 Category: Cancer & Oncology Source Type: news

Penn-developed approach could limit toxicity of CAR T therapy in acute myeloid leukemia
(University of Pennsylvania School of Medicine) A new approach pioneered at the University of Pennsylvania's Abramson Cancer Center may provide a new path towards treating acute myeloid leukemia (AML) with CAR T cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 31, 2018 Category: Cancer & Oncology Source Type: news

U.S. FDA Grants Priority Review to Astellas' New Drug Application for Gilteritinib for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
TOKYO, May 29, 2018 -- (Healthcare Sales & Marketing Network) -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D. "Astellas") announced today that the U.S. Food and Drug Administration (FDA) has accepted, with Priority R... Biopharmaceuticals, Oncology, FDA Astellas Pharma, gilteritinib, Acute Myeloid Leukemia, FLT3 (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 29, 2018 Category: Pharmaceuticals Source Type: news

U.S. FDA Grants Priority Review to Astellas' New Drug Application for Gilteritinib for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
TOKYO, May 29, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D. " Astellas " ) announced today that the U.S. Food and Drug Administration (FDA) has accepted, with Priority Review, the company's New Drug... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - May 29, 2018 Category: Drugs & Pharmacology Source Type: news

' Too Clean' Could Be a Trigger for Childhood Acute Leukemia'Too Clean' Could Be a Trigger for Childhood Acute Leukemia
A lack of microbial exposure among children in industrialized countries may contribute to the development of childhood B-cell acute lymphoblastic leukemia, say researchers.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 25, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Medical News Today: Early exposure to microbes may protect against childhood leukemia
A new analysis suggests that childhood acute lymphoblastic leukemia likely results from genetic predisposition and limited early exposure to germs. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 23, 2018 Category: Consumer Health News Tags: Leukemia Source Type: news

New 'unified theory' of childhood leukemia raises possibility of preventing the disease
Kids who develop acute lymphoblastic leukemia may be the victims of a triple-whammy stroke of bad luck, according to a provocative new theory from a respected British cancer researcher.If the explanation turns out to be correct, it would be good news for the most common type of childhood cancer:... (Source: Los Angeles Times - Science)
Source: Los Angeles Times - Science - May 23, 2018 Category: Science Authors: Melissa Healy Source Type: news

Imatinib-induced Fulminant Liver Failure in CML Imatinib-induced Fulminant Liver Failure in CML
Acute liver failure can be a fatal adverse effect of chronic myeloid leukemia treatment with imatinib. Is liver transplant a viable option for these patients?Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 23, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

' Best Survival Data Ever' in Young T-Cell Leukemia Patients'Best Survival Data Ever' in Young T-Cell Leukemia Patients
Moving nelarabine to the front line and combining it with methotrexate improved 4-year disease-free survival in young patients with T-cell acute lymphoblastic leukemia.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 22, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Ultra-Clean Homes Can Raise Childhood Cancer Risk, Study Finds
LONDON (CBS Local) – A groundbreaking study into what triggers cancer has found that children who are “too hygienic” and are kept away from other kids were at greater risk for developing leukemia. The Details: A cancer study has found that children living in ultra-clean environments have higher rates of leukemia Professor Mel Greaves says children need to have their immune system “primed” by exposure to various germs Greaves found that children with siblings or who were breastfed had lower rates of the disease Professor Mel Greaves from the Institute of Cancer Research (ICR) in London h...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - May 22, 2018 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News childhood cancer Children Chris Melore Germs Leukemia Local TV talkers Source Type: news

Most common childhood cancer 'partly caused by lack of infection'
Childhood acute leukaemia is caused by genetic mutations and a lack of childhood infection, scientists sayClean modern homes, antiseptic wipes and the understandable desire to protect small babies against any infection are all part of the cause of the most common form of childhood cancer, a leading expert has concluded after more than 30 years of research.Childhood acute leukaemia, says the highly respected Prof Mel Greaves, is nothing to do with power lines or nuclear fuel reprocessing stations. Nor is it to do with hot dogs and hamburgers or the Vatican radio mast, as have also been suggested. After the best part of a ce...
Source: Guardian Unlimited Science - May 21, 2018 Category: Science Authors: Sarah Boseley Health editor Tags: Cancer Health Cancer research Medical research Science Society Children Source Type: news

Leading UK scientist reveals likely cause of childhood leukaemia
(Institute of Cancer Research) A major new analysis reveals the likely cause of most cases of childhood leukaemia, following more than a century of controversy about its origins.Professor Mel Greaves assessed the most comprehensive body of evidence ever collected on acute lymphoblastic leukaemia (ALL). He concludes the disease is caused through a two-step process of genetic mutation and exposure to infection that means it may be preventable with treatments to stimulate or 'prime' the immune system in infancy. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 21, 2018 Category: Biology Source Type: news

A new Achilles' heel of blood cancer
(CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences) Acute Myeloid Leukemia is an aggressive form of blood cancer. The diseased cells often carry mutated forms of a specific gene, which is known to function within large protein networks. Applying a combination of proteomic and genomic screens, researchers at CeMM and LBI-CR identified a protein crucial for the survival of the cancer cells. When this protein is lost, AML cells stop growing and accumulate DNA damage, which makes them more sensitive to anti-cancer drugs. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 18, 2018 Category: Cancer & Oncology Source Type: news

Single surface protein boosts multiple oncogenic pathways in acute myeloid leukemia
(Rockefeller University Press) Researchers from the Albert Einstein College of Medicine in New York have discovered that a signaling protein elevated in patients with acute myeloid leukemia (AML) plays a much wider role in the disease than previously thought. The study, which will be published May 17 in the Journal of Experimental Medicine, raises hopes that current efforts to target this signaling protein could be a successful strategy to treat AML and other blood cancers. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 17, 2018 Category: Biology Source Type: news